- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
COMING SOON: Advances in Frontline Treatment for Advanced Renal Cell Carcinoma
June 30, 2022
Moshe Orenstein, MD, gives a brief overview of an exciting upcoming Targeted Oncology Virtual Tumor Board series titled "Advances in Frontline Treatment for Advanced Renal Cell Carcinoma."
Long-Term Survival Possible With Vincristine Plus Radiotherapy in Anaplastic Oligodendroglial Tumors
June 30, 2022
Findings from 2 studies suggest that long-term survival is possible in a significant proportion of patients with a 1p/19q co-deleted oligodendroglioma.
First Patient Dosed in Study of RMC-6236 in KRAS-Driven Advanced Solid Tumors
June 30, 2022
A phase 1/1b monotherapy clinical trial of RMC-6236 for the treatment of patients with advanced solid tumors driven by a variety of RAS mutations has dosed its first patient.
EP. 8B: Reactive and Proactive Treatment Approaches for the Management of Chemotherapy-Induced Myelosuppression
June 30, 2022
In this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.
Rusfertide May Reduce Need for Therapeutic Phlebotomy in Polycythemia Vera
June 30, 2022
Yelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide (PTG-300) in patients with chronic polycythemia vera.
New and Investigational Approaches to Anal Carcinoma Treatment
June 30, 2022
In an interview with Targeted Oncology, Charles J. Schneider, MD, FACP, provided an overview of the treatment landscape for anal carcinoma, and ongoing research.
Ruxolitinib Shows Superiority Over BAT in Second-Line, Inadequately-Controlled Polycythemia Vera
June 29, 2022
Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.
EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions
June 29, 2022
Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.
Ibrutinib/Venetoclax May Decrease Development of Resistance Mutations in Patients With CLL
June 29, 2022
Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.
Treatment Options Continue to Evolve for Hematologic Malignancies
June 29, 2022
During an interview with Targeted Oncology, Gunther Koehne, MD, PhD, explained the need to get experts together and discuss the increased activity of new developments for hematologic malignancies.
FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma
June 29, 2022
The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.
Case 3: CNS Data From Clinical Trials in HER2+ BC
June 29, 2022
A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.